Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Samsung Medical Center

Status and phase: Unknown; Phase 2

Conditions: Squamous NSCLC

Treatments: Drug: Dovitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT01861197

2012-09-070-002

Details and patient eligibility

About

Efficacy of Dovitinib for Squamous NSCLC.

Enrollment: 27 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed squamous NSCLC
• Previously treated with one or two lines of chemotherapy
• FGFR amplification (FISH > 5 copies of genes)
• 20 years or older
• ECOG PS 0-2

Exclusion criteria

• active infection
• uncontrolled brain metastasis
• unstable angina or MI

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 1 patient group

Dovitinib monotherapy

Experimental group

Treatment:

Drug: Dovitinib